InMed Pharmaceuticals (INM) Total Liabilities (2020 - 2026)

InMed Pharmaceuticals' Total Liabilities history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 0.72% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 0.72% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 18.0% from the prior year.
• Total Liabilities advanced to $2.2 million in Q1 2026 per INM's latest filing, from $1.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $4.6 million in Q1 2022 and bottomed at $1.3 million in Q3 2023.
• The 5-year median for Total Liabilities is $2.3 million (2025), against an average of $2.5 million.
• Across the five-year window, Total Liabilities surged 138.23% in 2022 and sank 62.55% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $2.6 million in 2022, then dropped by 3.92% to $2.5 million in 2023, then dropped by 6.57% to $2.3 million in 2024, then slumped by 30.88% to $1.6 million in 2025, then soared by 39.79% to $2.2 million in 2026.
• Per Business Quant, the three latest INM Total Liabilities figures stand at $2.2 million (Q1 2026), $1.6 million (Q4 2025), and $1.8 million (Q3 2025).